Accumulation of Sulphobutylether Beta Cyclodextrin Sodium in Critically Ill Patients Treated with Voriconazole
Author Information
Author(s): Marc A von Mach, Jürgen Burhenne, Ludwig S Weilemann
Primary Institution: University of Mainz
Hypothesis
This investigation aimed to determine first clinical data on sulphobutylether beta cyclodextrin sodium blood levels to verify the risk for accumulation.
Conclusion
The study found that sulphobutylether beta cyclodextrin sodium accumulates in patients treated with intravenous voriconazole and dialysis therapy, but no toxic effects were observed.
Supporting Evidence
- A 75-year-old woman showed a maximal sulphobutylether beta cyclodextrin sodium plasma level of 145 μg/ml initially, which decreased after renal function recovery.
- Three patients showed accumulation of sulphobutylether beta cyclodextrin sodium with maximum levels of 523 μg/ml, 409 μg/ml, and 581 μg/ml.
- No toxic effects were observed despite the accumulation of sulphobutylether beta cyclodextrin sodium.
Takeaway
Doctors checked how a medicine used for fungal infections builds up in the blood of very sick patients on dialysis, and they found it can accumulate but doesn't seem to cause harm.
Methodology
Plasma levels of voriconazole and sulphobutylether beta cyclodextrin sodium were measured in four patients with renal insufficiency receiving intravenous voriconazole.
Limitations
The study involved a small number of patients and lacked a control group.
Participant Demographics
The study included 4 patients with renal insufficiency, aged 18 to 75, with varying conditions such as acute myeloid leukemia and myocarditis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website